Serum-free and chemically-defined media offer customers better lot-to-lot consistency because they contain fewer undefined components, such as serum. Chemically-defined media contains components that are all known.
Maximizing the productivity, growth, and viability of CHO cell lines is an integral part of the development and commercialization of biotherapeutics. To help ensure this, the BalanCD CHO Media Platform delivers a scalable platform of chemically-defined, animal component-free growth and feed media that foster consistent growth and production at all phases:
|Discovery||Transfectory||Delivers milligram- to gram-scale yield of recombinant proteins using a simplified and affordable protocol|
|Cell Line Development||Growth A and Media Survey Panel||Delivers milligram- to gram-scale yield of recombinant proteins using a simplified and affordable protocol|
|Process Development & Scale-up||Growth A and Custom Media Services||Delivers higher protein titer and formulated to support full-scale commercial manufacturing|
|cGMP Manufacturing||Feed 4||Boost manufacturing outcomes with the growth and performance benefits of our most advanced, high-nutrient feed medium|
Purpose-built BalanCD CHO growth and feed media are formulated for industrial applications and for a smooth transition from early stage into commercial bioproduction. Scalability to a commercial batch size is ensured using a Rational Culture Media Design approach of sequential, complementary development methods to leverage our scientists’ knowledge of the effects of components and process parameters.
Designed to nurture and advance every step of development, the BalanCD CHO Media Platform provides reliable, consistent results from discovery to commercialization.
Serum-free and chemically-defined media are lower in protein content than media supplemented with serum, which can simplify the purification process and increase the yield of the end product. These media are free of animal-derived components, and only contain known chemical components.
Feed media are designed to provide cell culture nutrients for fed-batch process applications.
Hybridoma cells are a hybrid of a lymphocyte (usually a B-Cell) and a myeloma cancer cell. These cells are useful since they can produce monoclonal antibodies as opposed to polyclonal antibodies.
Insect cell lines, such as Sf9 and Sf21, support Baculovirus Expression Vector Systems (BEVS) and are frequently used for protein expression, including recombinant proteins and viral-like particles, as well as viral vector production.